Total Payments
$554,798
2024 Payments
$272,262
Companies
52
Transactions
1,368
Medicare Patients
2,165
Medicare Billing
$263,144
Payment Breakdown by Category
Other$446,203 (80.4%)
Travel$69,252 (12.5%)
Food & Beverage$28,265 (5.1%)
Consulting$10,678 (1.9%)
Research$400.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $334,772 | 156 | 60.3% |
| Honoraria | $111,432 | 51 | 20.1% |
| Travel and Lodging | $69,252 | 331 | 12.5% |
| Food and Beverage | $28,265 | 818 | 5.1% |
| Consulting Fee | $10,678 | 7 | 1.9% |
| Unspecified | $400.00 | 5 | 0.1% |
Payments by Type
General
$554,398
1,363 transactions
Research
$400.00
1 transactions
Ownership
$0
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| QOL Medical, LLC | $303,950 | 507 | $0 (2024) |
| Phathom Pharmaceuticals, Inc. | $156,854 | 189 | $0 (2024) |
| EVOKE PHARMA, INC. | $62,837 | 83 | $0 (2024) |
| Medtronic, Inc. | $10,073 | 58 | $0 (2024) |
| Allergan, Inc. | $6,894 | 40 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,195 | 120 | $0 (2024) |
| RedHill Biopharma Inc. | $1,976 | 21 | $0 (2023) |
| Ardelyx, Inc. | $1,603 | 16 | $0 (2024) |
| ABBVIE INC. | $1,565 | 84 | $0 (2024) |
| Covidien LP | $1,351 | 25 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $272,262 | 512 | Phathom Pharmaceuticals, Inc. ($156,854) |
| 2023 | $103,059 | 271 | QOL Medical, LLC ($84,565) |
| 2022 | $75,730 | 161 | QOL Medical, LLC ($37,643) |
| 2021 | $34,375 | 146 | QOL Medical, LLC ($30,756) |
| 2020 | $59,054 | 96 | QOL Medical, LLC ($57,977) |
| 2019 | $1,062 | 54 | Covidien LP ($282.13) |
| 2018 | $1,393 | 50 | Covidien LP ($577.54) |
| 2017 | $7,863 | 78 | Allergan Inc. ($6,805) |
All Payment Transactions
1,368 individual payment records from CMS Open Payments — Page 1 of 55
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $29.02 | General |
| Category: Gastroenterology | ||||||
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.83 | General |
| Category: Gastroenterology | ||||||
| 12/20/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: Alagille syndrome | ||||||
| 12/19/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $9.97 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/18/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/18/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $158.80 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/18/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $102.54 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/18/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $77.66 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/18/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $63.47 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/18/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | Cash or cash equivalent | $23.45 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $34.90 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/13/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $9.54 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | In-kind items and services | $1,040.90 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/12/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | In-kind items and services | $332.95 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/12/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $119.08 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $30.18 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $8.56 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $0.50 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/11/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/09/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $25.28 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/07/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $13.02 | General |
| Category: VIROLOGY | ||||||
| 12/06/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $0.50 | General |
| Category: VIROLOGY | ||||||
| 12/05/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | In-kind items and services | $288.95 | General |
| Category: GASTROENTEROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF PVP001, PVP002, AND PVP003 IN HEALTHY ADULTS AND PVP001 AND PVP002 IN ADULTS WITH CELIAC DISEASE | Takeda Pharmaceuticals U.S.A., Inc. | $400.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 487 | 581 | $336,885 | $59,686 |
| 2022 | 10 | 584 | 712 | $397,913 | $70,307 |
| 2021 | 10 | 575 | 712 | $389,787 | $70,972 |
| 2020 | 8 | 519 | 661 | $280,542 | $62,179 |
Total Patients
2,165
Total Services
2,666
Medicare Billing
$263,144
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 70 | 70 | $99,750 | $15,589 | 15.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 105 | 160 | $33,920 | $15,351 | 45.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 66 | 99 | $19,800 | $6,300 | 31.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 41 | 41 | $12,300 | $4,483 | 36.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 59 | 62 | $57,350 | $4,069 | 7.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 34 | 34 | $11,152 | $3,766 | 33.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 36 | 36 | $44,814 | $3,426 | 7.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 13 | 13 | $17,330 | $2,353 | 13.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 35 | 38 | $5,700 | $2,120 | 37.2% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 12 | 12 | $15,249 | $2,017 | 13.2% |
| 45381 | Injection beneath lining of large bowel using a flexible endoscope | Facility | 2023 | 16 | 16 | $19,520 | $213.15 | 1.1% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 66 | 72 | $102,600 | $15,318 | 14.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 93 | 141 | $29,892 | $12,850 | 43.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 97 | 154 | $30,800 | $8,892 | 28.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 70 | 75 | $22,500 | $8,261 | 36.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 57 | 57 | $18,696 | $7,237 | 38.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 65 | 68 | $84,252 | $6,477 | 7.7% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 21 | 22 | $28,283 | $3,859 | 13.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 59 | 59 | $53,100 | $3,682 | 6.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 39 | 47 | $7,050 | $3,346 | 47.5% |
| 45381 | Injection beneath lining of large bowel using a flexible endoscope | Facility | 2022 | 17 | 17 | $20,740 | $384.96 | 1.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 101 | 158 | $33,496 | $15,667 | 46.8% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 70 | 70 | $99,750 | $15,503 | 15.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 94 | 163 | $32,600 | $9,977 | 30.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 60 | 60 | $19,680 | $7,681 | 39.0% |
About Dr. Daksesh Patel, D.O
Dr. Daksesh Patel, D.O is a Gastroenterology healthcare provider based in Evanston, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/15/2007. The National Provider Identifier (NPI) number assigned to this provider is 1154526770.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daksesh Patel, D.O has received a total of $554,798 in payments from pharmaceutical and medical device companies, with $272,262 received in 2024. These payments were reported across 1,368 transactions from 52 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($334,772).
As a Medicare-enrolled provider, Patel has provided services to 2,165 Medicare beneficiaries, totaling 2,666 services with total Medicare billing of $263,144. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Evanston, IL
- Active Since 06/15/2007
- Last Updated 07/21/2022
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1154526770
Products in Payments
- SUCRAID (Drug) $161,356
- VOQUEZNA (Drug) $156,854
- Sucraid (Drug) $142,594
- GIMOTI (Drug) $62,837
- LINZESS (Drug) $6,880
- GI GENIUS (Device) $2,545
- Talicia (Drug) $1,976
- IBSRELA (Drug) $1,603
- ENTYVIO (Biological) $1,355
- ESOPHYX (Device) $783.60
- XIFAXAN (Drug) $710.59
- GI Genius (Device) $689.49
- DUPIXENT (Biological) $632.91
- Bravo (Device) $513.21
- SKYRIZI (Biological) $442.84
- Barrx (Device) $373.62
- Entyvio (Biological) $365.48
- STELARA (Biological) $290.18
- HEMOSPRAY (Device) $255.42
- HUMIRA (Biological) $248.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Evanston
Eugene Yen, Md, MD
Gastroenterology — Payments: $218,003
Gastroenterology $218,003
Dr. John Vainder, Md, MD
Gastroenterology — Payments: $9,597
Gastroenterology $9,597
Dr. Harsh Gupta, Md, MD
Gastroenterology — Payments: $5,751
Gastroenterology $5,751
Farhan Quader, Md, MD
Gastroenterology — Payments: $3,991
Gastroenterology $3,991
Anuhya Gampa, M.d, M.D
Gastroenterology — Payments: $1,393
Gastroenterology $1,393
Laura Bianchi, Md, MD
Gastroenterology — Payments: $1,120
Gastroenterology $1,120